Business

Roche gets approval for new cancer treatment

Associated Press/File

WASHINGTON — The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.

The agency cleared Gazyva to fight chronic lymphocytic leukemia in combination with chemotherapy in patients who haven’t previously been treated for the disease.

Advertisement

Gazyva works by killing cancer cells and encouraging the immune system to fight against them.

The FDA approved the drug based on a study showing Gazyva plus chemotherapy was superior to chemotherapy alone at slowing the progress of the disease.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

The injectable biotech drug is the first medicine approved under FDA’s breakthrough designation, which was authorized by Congress last year. The new designation is designed to speed up the approval of promising drugs by providing companies with extra meetings and earlier communication with FDA scientists to discuss drug development.

Associated Press

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.